Dutcher JP - Search Results

1

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. McDermott DF, et al. Among authors: dutcher jp. Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424850 Free PMC article. Clinical Trial.

2

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, et al. Weiss GR, et al. Among authors: dutcher jp. J Clin Oncol. 1992 Feb;10(2):275-81. doi: 10.1200/JCO.1992.10.2.275. J Clin Oncol. 1992. PMID: 1732429 Clinical Trial.

3

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss G, et al. Dutcher JP, et al. J Clin Oncol. 1991 Apr;9(4):641-8. doi: 10.1200/JCO.1991.9.4.641. J Clin Oncol. 1991. PMID: 2066760 Clinical Trial.

4

A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

Sznol M, Mier JW, Sparano J, Gaynor ER, Weiss GR, Margolin KA, Bar MH, Hawkins MJ, Atkins MB, Dutcher JP, et al. Sznol M, et al. Among authors: dutcher jp. J Biol Response Mod. 1990 Dec;9(6):529-37. J Biol Response Mod. 1990. PMID: 2074439 Clinical Trial.

5

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH, et al. Parkinson DR, et al. Among authors: dutcher jp. J Clin Oncol. 1990 Oct;8(10):1650-6. doi: 10.1200/JCO.1990.8.10.1650. J Clin Oncol. 1990. PMID: 2213101 Clinical Trial.

6

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, Parkinson D, Ciobanu N, Fisher RI, Boldt DH, et al. Dutcher JP, et al. J Clin Oncol. 1989 Apr;7(4):477-85. doi: 10.1200/JCO.1989.7.4.477. J Clin Oncol. 1989. PMID: 2647913 Clinical Trial.

7

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, et al. Margolin KA, et al. Among authors: dutcher jp. J Clin Oncol. 1989 Apr;7(4):486-98. doi: 10.1200/JCO.1989.7.4.486. J Clin Oncol. 1989. PMID: 2647914 Clinical Trial.

8

Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.

Sznol M, Dutcher JP, Atkins MB, Rayner AR, Margolin KA, Gaynor ER, Weiss GR, Aronson F, Parkinson DR, Hawkins MJ. Sznol M, et al. Among authors: dutcher jp. Cancer Treat Rev. 1989 Jun;16 Suppl A:29-38. doi: 10.1016/0305-7372(89)90020-0. Cancer Treat Rev. 1989. PMID: 2670213 Review. No abstract available.

9

Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma.

Wadler S, Einzig AI, Dutcher JP, Ciobanu N, Landau L, Wiernik PH. Wadler S, et al. Among authors: dutcher jp. Am J Clin Oncol. 1988 Feb;11(1):55-9. doi: 10.1097/00000421-198802000-00012. Am J Clin Oncol. 1988. PMID: 3277375 Clinical Trial.

10

Morphologic and ultrastructural evidence of interleukin-6 induced platelet activation.

Oleksowicz L, Mrowiec Z, Isaacs R, Dutcher JP, Puszkin E. Oleksowicz L, et al. Among authors: dutcher jp. Am J Hematol. 1995 Feb;48(2):92-9. doi: 10.1002/ajh.2830480205. Am J Hematol. 1995. PMID: 7531395

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

295 results

Search Page

Filters